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Abstract
Background: Venous leg ulcers constitute a chronic recurring complaint that affects 1.0–1.3% of the adult population at some
time in life, and which corresponds to approximately 75% of all chronic ulcers of the leg. Multilayer compression bandaging is,
at present, the only treatment that has been proved to be effective in treating this type of ulcer. There is no consensus, however,
about the dressings that may be applied, beneath the compression, to promote the healing of this type of ulcer, as there does
not seem to be any added benefit from using special dressings rather than simple, low-adherence ones. As well as analgesia,
acupuncture provokes peripheral vasodilation, in skin and muscles – which has been demonstrated both experimentally and in
clinical practice – probably due to the axon reflex, among other mechanisms. The aim of the present study is to measure the
effectiveness and cost of compression treatment for venous leg ulcers combined with special dressings, in comparison with low-
adherence ones and acupuncture.
Methods/design: Cluster-randomized open-labeled trial, at 15 primary healthcare clinics in the Sevilla-Sur Healthcare District,
with a control group treated with compression bandaging and low-adherence dressings; the experiment will consist, on the one
hand, of the compression treatment applied in combination with special dressings (Treatment 1), and on the other, the
compression treatment applied in association with low-adherence dressings, together with acupuncture (Treatment 2).
Discussion: The results will be measured and recorded in terms of the median time elapsed until complete healing of the ulcer,
and the rate of complete healing at 3 months after beginning the treatment. An economic analysis will also be made.
This study, carried out in the context of real clinical practice, will provide information for decision-taking concerning the
effectiveness of special dressings. Moreover, for the first time a high-quality study will evaluate the effectiveness of acupuncture
in the process of healing venous leg ulcers.
Trial registration: Current Controlled Trials ISRCTN26438275.
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Venous leg ulcers (VLU) constitute a chronic recurring
complaint that affects 1.0–1.3% of the adult population at
some time in life, and which corresponds to approxi-
mately 75% of all chronic ulcers of the leg [1]. They are
caused by sustained venous hypertension, which is the
result, in almost 50% of cases, from superficial venous
insufficiency or from malfunctioning valves in perforating
veins, with a normally-functioning deep venous system.
Other factors that may result in sustained venous hyper-
tension are those that impede the pumping function of
the leg muscles, such as conditions that reduce spontane-
ous movements (Parkinson's disease, stroke, spinal cord
injuries or excessive sedation). This type of chronic
venous insufficiency is characterized by oedema, venous
dilation, painful legs and stasis dermatitis. VLU patients
have a worse quality of life than non-affected persons of
the same age due to the pain, malodour and loss of inde-
pendence that it causes [2]. The precise procedure by
which hypertension leads to ulceration has yet to be clar-
ified, but various mechanisms are known to be capable of
intervening in its development and maintenance, such as
plasma extravasation, pericapillary deposits of fibrin [3],
disorders of the fibrinolytic system [4], the fixing or reten-
tion of growth factors by macromolecules in the dermis,
or leukocytes in the veins of the legs [5-7].
In the USA, VLUs have been estimated to cost a billion
dollars a year, representing an average cost of over 40,000
dollars during the lifetime of each patient [1], without tak-
ing into account the financial effects of impaired quality
of life, sick leave and frequent hospitalization. In the
United Kingdom, the average cost of treating venous
ulcers varied between 814 to 1,994 euros per year, of
which a large proportion is devoted to nursing expenses
[8,9]. In Europe, the total cost of VLU treatment amounts
to 1% of the annual healthcare budget [10], with an esti-
mated mean cost of 250 euros in Spain per patient, per
year of treatment [11].
Developing a healthcare plan for VLU patients includes
curing active ulcers and preventing relapses. To achieve
these goals, such a plan must address the treatment of
infections associated with these ulcers, preventing the
development of infection, stimulating granulation and
epithelial tissues, compression, raising the leg position,
improving mobility, reducing obesity, improving nutri-
tion and, in some cases, performing surgery [12,13].
Perhaps the most controversial aspect of the local treat-
ment of VLUs concerns the type of dressings to use [14].
The use of wet dressings has been shown to favour granu-
lation and epithelialization processes and, therefore, the
healing of the ulcer, but no evidence has been provided to
assist in choosing between special dressings and simple,
low-adherence ones [15]. The application of external
compression causes various complex physiological and
biochemical effects that affect the venous, arterial and
lymphatic systems. Provided the degree of compression
does not adversely affect arterial blood flow, and that the
correct techniques and materials are applied, the effects of
compression may be very positive, reducing oedema and
pain, whilst at the same time favouring the healing of
ulcers caused by venous insufficiency. However, there are
many ways in which this compression may be applied,
and there is no consensus as to which is best [16].
Depending on the size of the ulcer, healing rates with
compression treatment range from 40–70% at three
months to 50–80% at 6 months [17,18]. The latest sys-
tematic review carried out by the Cochrane Collaboration
recommends compression therapy and low-cost, low-
adherence dressings as a first-line treatment for healing
VLUs [15].
In addition to analgesia, acupuncture provokes peripheral
vasodilation in the skin and in muscles, probably due to
the axon reflex [19-21]. Stimulation of Aδ and C fibres
releases vasoactive neuropeptides, as well as proinflam-
matory agents like the calcitonin gene? related peptide
(CGRP), the P substance (SP), neurokinin A (NKA), opio-
ids, galanin, somatostatin and vasoactive intestinal pep-
tide (VIP) [22,23]. Deep, prolonged vasodilation may also
be mediated by CGRP [24-26]. Some studies have sug-
gested that the neuropeptides released by sensory nerve
stimulation are beneficial in maintaining skin integrity
[23,27,28], for healing ulcers [29,30] and for peripheral
vascular disorders [31,32]. Another key element in regu-
lating the vascular tone and the blood flow is the endothe-
lial synthase of nitric oxide (NO), which is responsible for
catalyzing the NO [33], which is active in arteriolar
vasodilation and reduces peripheral resistance, facilitating
normal blood flow to the tissues [34]. It has been shown
that the expression of NO-synthase (NOS) is greater in
skin regions where acupuncture points and channels are
located. In these areas, moreover, there are raised levels of
NO in the blood after acupuncture [35,36], which sug-
gests that the acupunctural stimulation of the sensorial
nerves may act as an in vivo modulator of NO levels [32].
Although studies have been carried out to examine the
effectiveness of acupuncture in treating VLUs, these have
been of poor quality and have reported contradictory
results [37-39].
In this paper, we propose a multicentre cluster-rand-
omized study, with a predetermined sample size, and
appropriate follow up, assessing the patients' quality of
life and employing an objective results measure that will
enable us to accurately evaluate the length of time needed
for patients' ulcers to heal, thus meeting the recommenda-Page 2 of 10
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[15,16].
Methods/Design
Research aims and questions
The aim of this study is to determine whether the combi-
nation of compression bandaging with simple, low-
adherence dressings and acupuncture is more effective
than when the same bandaging is employed in combina-
tion with special dressings or with simple, low-adherence
dressings, but no sensory stimulation (acupuncture), with
respect to the complete healing of venous leg ulcers.
The following research questions are proposed:
▪ In terms of the healings of venous leg ulcers, is it better
to employ compression bandaging associated with sen-
sory stimulation (acupuncture) and simple dressings,
than the same bandaging without sensory stimulation,
with special dressings, or than the compression bandag-
ing without sensory stimulation and with simple dress-
ings?
▪ What are the differences between healing treatments
with special dressings and those with simple, low-adher-
ence ones, in terms of the complete healing of venous leg
ulcers?
▪ How long does it take for venous leg ulcers to recur?
▪ How effective is the treatment in terms of reducing pain
intensity?
▪ How effective is the treatment in terms of reducing the
amount of analgesic and anti-inflammatory medicines
consumed?
▪ Are there any quality of life changes related to the health
of patients with venous leg ulcers?
▪ What is the total financial cost of each of the treatments
studied?
▪ What is the cost-effectiveness ratio of the treatments
studied, for patients with venous leg ulcers?
▪ What is the opportunity cost of treatments not imple-
mented?
Design
Open-labeled, controlled multicentre prospective study,
with random cluster allocation to treatment groups (Pri-
mary Healthcare Clinics) in the Sevilla-Sur Health District





patients with venous leg ulcers who request treatment at
the Primary Healthcare Clinic.
Study population
patients with venous leg ulcers who request treatment by
a healthcare professional (doctor or nurse) at one of the
Primary Healthcare Clinics in the Sevilla-Sur Health Dis-
trict taking part in the study, with at least one active
venous leg ulcer (open, CEAP C6 [40] with a diameter
exceeding 1 cm.
Patients with one or more of the following will be
excluded from the study:
▪ Arterial pathology (systolic pressure in the ankle of less
than 80 mm Hg or ankle/arm systolic index less than 0.8).
▪ Diabetic ulcer of the foot, rheumatoid arthritis or sys-
temic vasculitis.
▪ Use of anticoagulants
▪ Pregnancy
Sampling units
the Primary Healthcare Clinics participating in the study.
Analysis units
per Healthcare Clinic (according to the group assigned)
and per patient.
Randomization and blinding procedure
a list of random numbers will be created, using statistical
software, to which the researchers involved in the study
will not have access. This list will be applied to the list of
participating Clinics until the clusters for each group are
obtained. Three types of cluster will be used, according to
the treatment for the venous leg ulcer provided at the
Clinic (A: compression therapy plus simple, low-adher-
ence dressings and acupuncture; B: compression therapy
plus special dressings; C: compression therapy plus sim-
ple, low-adherence dressings). Before beginning, the list
of Clinics will be randomly ordered, by drawing lots
blindly, with no repetitions, from a bag containing the
names of all the Clinics taking part. None of those partic-
ipating in this process will belong to the research group,
and none of them will play any further part in the study.Page 3 of 10
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The ethical validity of this study has been analyzed and
approved by the Andalusian Government Committee for
Clinical Trials, following the approval of the correspond-
ing Research Commission at each of the participating
Clinics. The study design takes into account the funda-
mental principles set out in the Helsinki Declaration, and
those of the Council of Europe Convention concerning
human rights and biomedicine, as well as the require-
ments under Spanish law in the field of biomedical
research, the protection of personal data, and bioethics.
All the patients involved must sign their informed consent
to the proposed clinical research procedures. During the
course of the study, audits will be performed as required
by the relevant Research and Ethics Committee, as well as
those of each Clinic's Quality Committee, independently
of any external audits (such as that of the research financ-
ing body) that may be necessary.
Sample size
The sample size has been calculated following the param-
eters of Campbell et al. [41], on the basis of historical data
[18]. The success rate for complete healing of venous leg
ulcers at 3 months, with compression bandaging plus spe-
cial dressings, is 44%. With an alpha (significance) level
of 0.05 and a power of detection of differences of 80%,
assuming a two-tailed approach, the total sample size
needed will be 375 patients, in order to detect differences
of 15% between the groups, as regards the rate of com-
plete healing of venous leg ulcers at 3 months. This calcu-
lation assumes a possible dropout rate of 5% and an intra-
cluster coefficient of correlation of 0.05 (according to the
expected variance of the response within a single cluster).
There will be 15 clusters (Primary Healthcare Clinics) and
so each Clinic will need to recruit 25 subjects. Therefore,
3 treatment arms will be formed, with 125 patients in
each (with 5 Clinics per arm).
Interventions
The compression treatment and application of dressings
will be performed in accordance with the standard proce-
dure and the criteria of the nursing staff responsible. A pri-
ori, one treatment session per week is planned, but this
may be modified in the light of the patient's response. Fol-
low up of the patients recruited into this study will be con-
tinued for one year after the randomization process. The
acupuncture sessions in Group A will be given at the same
time as the cleansing of the ulcer and the changing of the
compression bandage, and will continue for 3 months, or
until the ulcer has healed completely (whichever occurs
first). If, after these 3 months, the ulcer has not healed, the
sessions will be continued (as before, together with the
cleansing of the ulcer) for another 3 months. The acu-
puncture treatment will not be continued for longer than
6 months (figure 1).
The patients taking part in the study will be given recom-
mendations about suitable hygiene-posture routines
(resting with the legs raised, not standing for long periods,
taking regular walks, keeping the skin well hydrated) and
nutritional advice, if necessary. Both the compression
treatment and the application of dressings will continue
until the ulcer has completely healed. If a recurrence
occurs before the one-year follow-up period has ended,
the patient will be entered into a sub-cohort and given a
new treatment plan.
Compression therapy (Groups A, B and C in the study)
Compression therapy will be given to all the participants
in the study. Once the patient has been examined and the
ankle/arm index calculated by means of a Doppler scan,
an evaluation will be made of the state of the skin and of
the shape of the leg, after confirming the absence of neu-
ropathology, arterial pathology and cardiac insufficiency.
The bandaging will be of a Class 3, high-compression
multilayer type [42], following cleansing and application
of the dressing, as follows: 1) With a 50% overlap, apply
a cotton bandage in a spiral pattern from the base of the
toes to just below the knee, without imposing any ten-
sion; 2) Apply an elastic bandage in a spiral pattern, with
50% overlap and stretched to 50% of its extension, from
the base of the toes to just below the knee; 3) Apply a
cohesive elastic bandage, with 50% overlap and stretched
to 50% of its extension, from the base of the toes to just
below the knee, and apply light pressure to ensure the
adherence of the bandage. The oedema of the leg should
be reduced by raising the limb for 15 minutes before
applying compression.
Treatment of the ulcer for the patients given low-adherence, simple 
dressings (Study groups A and C)
▪ Cleaning: with tap water and mild soap [43-45], fol-
lowed by careful drying
▪ Debridement: if necrotic tissue or sloughing are
observed, perform enzymatic debridement, which may be
combined with excision debridement, if necessary
▪ Managing infection: if infection is suspected, take a sam-
ple and begin treatment with silver sulfadiazine for a max-
imum of 2 weeks. If a culture study confirms the infection,
treat using oral antibiotics
▪ Dressings: simple, low-adherence type (paraffin-impreg-
nated tulle gras)
Any adverse reaction or side effect that may occur should
be recorded in the Data Record (DR), with a detailed
description and the date of occurrence.Page 4 of 10
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Flow diagram for the study. Flow diagram for the diverse phases of the study.
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group B)
▪ Cleaning: with tap water and mild soap, followed by
careful drying
▪ Debridement: if necrotic tissue or sloughing are
observed, perform enzymatic debridement, which may be
combined with hydrogel to favour autolysis. If necessary,
excision debridement should be applied
▪ Managing infection: if infection is suspected, take a sam-
ple and begin treatment with silver dressings (hydrofibre
or hydropolymer) for a maximum of 2 weeks. If a culture
study confirms the infection, treat using oral antibiotics
▪ Dressings: Cover with hydropolymers. Use alginate or
hydrofibre dressings if exudate must be controlled
Any adverse reaction or side effect that may occur should
be recorded in the DR, with a detailed description and the
date of occurrence.
Acupuncture (Study Group A)
The nursing staff will be trained in the specific techniques
of localization, puncture and manipulation in order to
apply acupuncture at the perilesional zone of the ulcer(s),
in healthy skin, using 4–8 needles, and at 2 points located
on either side of the tibial crest of the affected limb (Yin-
lingquan SP9 and Zusanli ST36). The puncture will be car-
ried out after cleansing of the ulcer. The needle to be
inserted is a sterile, single-use filiform acupuncture nee-
dle, 30 mm long and 0.30 mm in diameter, fitted with a
guide tube (S-J3030, manufactured by Seirin Corpora-
tion). Application will be made at each of the above-men-
tioned points, after sterilizing the skin, and with the
patient lying face up or sideways. The puncture will be
made vertically, unless otherwise specified, to a depth of
10–28 mm. The insertion will be followed by broad bidi-
rectional rotational movements of the needle handle in
order to produce the sensation of Deqi, commonly
described as an irradiated feeling. The needle will be held
in place for 20 minutes, and moved for 10 seconds every
5 minutes (4 manipulations per session). The acupunc-
ture sessions will be applied for the first 3 months of this
treatment programme or until the ulcer has completely
healed. If complete healing is not achieved in this period,
the sessions may be prolonged for another 3 months, after
which the acupuncture treatment will be discontinued.
For each session, the number of needles used and the
exact location of their application will be recorded. Any
adverse reaction or side effect arising from this treatment
should be recorded in the DR, with a detailed description
and the date of occurrence.
A priori, the ulcer should be cleansed once weekly, the
same frequency as the sensory stimulation with acupunc-
ture. Nevertheless, this may be increased or decreased, at
the discretion of the nursing staff.
All treatment will be given by the professional healthcare
staff (nurses) employed at the Primary Healthcare Clinics,
coordinated by the treatment programme head in each
case. In order to standardize criteria and training proce-
dures in the use of compression bandages, the data record
system and the application of the study treatments, a spe-
cific ad-hoc training course will be given to all the
healthcare staff involved in the study. This training will be
structured as follows:
▪ Aims: acquisition of skills in applying acupuncture pro-
tocols for venous ulcers, in applying treatment techniques
using the different kinds of dressing and in using the data
record system. Standardization of criteria for applying
compression bandages.
▪ Content: differential diagnosis of leg ulcers, calculation
of the ankle/arm index, selection and localization of acu-
puncture points, the insertion of needles, the preparation
and application of ulcer cleansing treatment, the reaction
to possible infection, training in techniques with com-
pression bandages, giving instructions to patients, imple-
menting follow up, and giving all the study participants
hygiene, posture and nutrition recommendations
▪ Instruction method: workshop
▪ Duration: 10 teaching hours
Outcome measures
Primary outcome
Time until complete healing is achieved
Complete healing is defined as the complete epithelializa-
tion of all the leg venous ulcers, not just the reference one.
Secondary outcome variables
Complete healing at 3 months after beginning treatment
Complete healing is defined as the complete epithelializa-
tion of all the leg venous ulcers, not just the reference one
(table 1).
Changes in the size of the surface area of the ulcer (in cm2)
When the baseline evaluation is made, the ulcer will be
measured; if there are more than one, the largest ("the
main ulcer") will be assessed. Nevertheless, the outcome
variable of complete healing will be determined on the
basis of all the ulcers observed on the patient when the
baseline assessment is made. The area of the ulcer will be
calculated using a compact digital tablet (Visitrak), with
which the area can be assessed quickly, conveniently andPage 6 of 10
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sheet used as the digital screen; this has three layers to
minimize the risk of cross contamination or secondary
infection, and the layer in contact with the patient is ster-
ile. The surface on which the data are recorded is kept
clean and may be included in the patient's case history.
Pain intensity measured on a visual analogue scale
There exists sufficient evidence to corroborate the validity
of the visual analogue scale of pain intensity. Many stud-
ies have demonstrated the validity of the concept [46] and
its reliability [47,48]. With this method, the subjective
intensity of pain may be measured quickly and straight-
forwardly. The patient is asked to mark the degree of pain
intensity on a millimetric scale, from 0 (no pain) to 100
(the worst pain imaginable).
Changes in the health-related quality of life at 3, 6 and
12 months (12-item Short Form health survey, version 2)
[49].
Adverse events – Adverse effects
A record will be kept of any adverse events or adverse
effect observed by healthcare staff or reported by the
patient or by his/her carer.
Cost-utility
Health utility will be measured in terms of the quality-
adjusted life years (QALY) gained for each patient, calcu-
lated from the area beneath the SF-12 curve at 3 months
from the start of treatment.
Opportunity cost
this will include the sum of the outputs from the activities
potentially left undone as a result of providing a given
treatment, rather than a possible alternative, together with
the potential financial cost of the resources employed.
Using the ABC method, the resources imputed to each
patient will be distributed in a multidisciplinary table
based on a modular "counter"-type framework for each
case, in order to apply the analytical model and to obtain
the SF-12 curve showing the variation in health-related
quality of life and the potential cost savings for the Public
Healthcare System.
Covariables
The covariables recorded will be the patient's age, sex,
educational level, occupation, income, weight (kg),
height (cm), mobility, systolic arterial pressure, diastolic
arterial pressure, arm/ankle index and ankle diameter
(cm), the duration of the active ulcer (weeks), the location
of the ulcer (if more than one ulcer is present, stating the
location of the largest one, which is taken as the reference
ulcer), whether the ulcer is unilateral or bilateral, the
number of ulcers on the leg(s), whether the ulcer is new or
recurrent (in the latter case, recording the time since the
first appearance, in years and months), the signs of gran-
ulation at the base of the ulcer, the signs of epithelializa-
tion at the edges of the ulcer, the presence of fibrinous
and/or necrotic tissue, the presence of lipodermatosclero-
sis, and the presence of infection. Other variables
recorded will include dependence on tobacco, alcohol or
other psychoactive substances, the presence of diabetes
mellitus, the results of a nutritional study (haemogram
and biochemical tests: albumin, prealbumin, transferrin
Table 1: Outcome measures. Work scheme with description of assessment visits and times.
Baseline (T0) Weekly 
treatment





Evaluation at 6 
months (T2)





Localization of ulcer(s) X X X X
Area of main ulcer X X X X X X
Duration of the main ulcer X
Exudate culture (if necessary) X X X X X X
Changes in the size of the main ulcer X X X X X
Characteristics of the main ulcer X X X X X X
Complete healing (date) X X X X X
Pain intensity X X X X X
SF-12 X X X X
Adverse events/effects X X X X X
Compliance with hygiene-posture 
recommendations
X X X X
Location of treatment (clinic/home) X X
Time employed in treatment X X
Materials employed in treatment X X
Number of needles used(Group A) X X
Obtention of Deqi (Group A) X XPage 7 of 10
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occurs (weeks), compliance with hygiene-posture recom-
mendations, self care, and the assistance or otherwise of
non-professional carers. In addition, a record will be kept
of all medication taken (corticoids, immunosuppressors,
anticoagulants, etc.) and information about possible cul-
tures of the ulcer exudate.
Data handling
The data on the variables of interest will be recorded on a
purpose-designed form to be completed by each
researcher at each clinic. This information will be entered
into a database for subsequent statistical analysis.
Data collection
The routine follow-up evaluation, to be made following
cleansing session, will be performed by the nursing staff
responsible. The baseline evaluation (T0), that of the
results at 3 months (T1), and the follow-up evaluations at
6 and 12 months (T2 and T3) will be carried out by the
healthcare personnel responsible for the treatment pro-
gramme (and who will be blinded with respect to the
group to which each patient is assigned).
Measurements (measurement times)
Baseline evaluation basal (T0)
▪ The data obtained in the examination made prior to
beginning treatment will include personal and sociode-
mographic characteristics, background and case history,
ankle/arm index, nutritional status, previous treatment
received, results of the ulcer exudate culture, the dimen-
sions of the ulcer and observations regarding its condi-
tion, location and duration in an active state, as well as
about the patient's health-related quality of life.
▪ Follow up. At each visit, the nurse applying the treatment
will record the macroscopic status of the ulcer, any adverse
events that may have occurred, the time employed in pro-
viding the treatment, the location of the treatment (clinic/
home) and the name of the person performing it. If total
healing of the ulcer is detected during a routine examina-
tion, the treatment programme official at the relevant
Clinic should be informed. For the patients in Group A, a
record should also be kept of the data concerning the acu-
puncture session (the number and location of local
points).
Follow-up evaluation at 3 months after starting treatment (T1)
At three months after starting the treatment, a fresh assess-
ment will be made of the patient's condition, quality of
life and compliance with hygiene-posture recommenda-
tions, as well as of the physical status of the ulcer (appear-
ance and size).
Follow-up evaluation at 6 months after starting treatment (T2)
With the same content as the previous evaluation.
Follow-up evaluation at 12 months after starting treatment (T3)
With the same content as the previous evaluation.
Data analysis
The data analysis will be carried out by personnel blinded
to the treatment groups, and for two types of populations:
(1) intention to treat (ITT), with all the patients rand-
omized; (2) per protocol (PP), including only the patients
with no more than slight variances from the protocol.
The baseline variables for the different groups will be
compared, to test the homogeneity produced by random
allocation, in terms of differences of the means and of
proportions, and the only differences taken into consider-
ation in this comparison will be those that are clinically
relevant for subsequent analysis. The magnitude of the
difference in any imbalance produced by the random allo-
cation to groups will be evaluated by using ratios of the
means, or medians, or proportions, bearing in mind
whether the level of analysis is per cluster or per individ-
ual.
The final analysis will be carried out as a univariate sur-
vival analysis (using the Kaplan-Meyer method and the
log-rank-test for inter-group comparison). The hazard
ratios for each treatment will be calculated, together with
the corresponding NNTs, calculating a 95% confidence
interval, using Cox's proportional risk regression model.
The assumption of proportionality will be assessed from
the interaction between the time elapsed until success
(total healing) and treatment group, and will be tested
graphically by observing the parallelism in the log-log
curves. A multilevel analysis will be carried out to adjust
for possible unbalanced variables in the baseline analysis,
taking the patients as level 1 and the Primary Healthcare
Clinics as level 2. The interactions between clinic and
treatment group will be examined, as will the possible var-
iability in the intercept. The level of significance will be set
at p < 0.05, for all the tests made. Cost-effectiveness, cost-
utility and opportunity cost analyses will be made.
Discussion
We have identified three shortcomings in the present
study design: the first arises from its conceptualization, in
attempting to measure the effectiveness of procedures
(acupuncture) whose efficacy has yet to be proven. It
might be argued that a previous step should be to design
a double-blinded study of effectiveness, comparing the
above methods with a placebo procedure. However, apart
from the impossibility of implementing a double-blind
test for acupuncture, our viewpoint is to seek to determine
the validity of clinical practices that are feasible in prag-Page 8 of 10
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bility of the effects produced by nursing care; nevertheless,
the cluster design employed is aimed at minimizing the
risk of habit-formed contamination in the treatments
applied and that of contamination between patients, in
the sense of their sharing information about the results.
These problems are addressed by standardizing the proto-
cols/procedures and by organizing meetings to standard-
ize the criteria applied, as well as by performing an a
posteriori statistical analysis of the influence of the "ther-
apist" factor. Finally, the fact that the outcome variable
assessed is that of the complete healing of all leg venous
ulcers suffered by the patient complicates analysis, but we
believe a more limited study would have less probability
of being of interest to patients concerned with the time
elapsed until the complete healing of all their ulcers.
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